Wibmer Andreas, Meyer Bernhard, Albrecht Thomas, Buhr Heinz-Johannes, Kruschewski Martin
Department of General, Thoracic and Vascular Surgery, Campus Benjamin Franklin, Charité University Medicine, Berlin, Germany.
Cardiovasc Intervent Radiol. 2009 Sep;32(5):918-22. doi: 10.1007/s00270-009-9538-2. Epub 2009 Mar 19.
Several studies have observed both higher mortality rates and lower utilization of endovascular aneurysm repair (EVAR) at low-volume centers. This article presents the results of elective abdominal aortic aneurysm (AAA) repair at a low-volume center in the endovascular era and investigates whether postprocedural mortality can be improved by extension of EVAR application also in this setting. This is an 11.6-year retrospective cohort study of 132 patients undergoing elective surgical or endovascular AAA repair at a tertiary care academic hospital between 1997 and July 2008, i.e., a median volume of 12 cases per year. The study was divided into two periods of time according to the respective indications and contraindications for EVAR, which substantially changed in 2005. During period 1, only aneurysms with necks > or =20 mm long and not involving the iliac arteries were treated endoluminally. Beginning in 2005, indication for EVAR was expanded to aortoiliac aneurysms with a minimum neck length of 15 mm. Preoperative risk was assessed by the SVS/AAVS comorbidity score. During the first period (1997-2004) 18.4% (16/87) of all patients received EVAR. By extending anatomical confines and indications for EVAR in 2005, the utilization rate of EVAR increased to 40.0% (18/45) during the second period (2005-July 2008; p = 0.007). Prevalence of preoperative risk factors did not change during the two observation periods. In contrast to period 1, high-risk patients were preferentially treated endoluminally during the second period, resulting in a significantly higher median SVS/AAVS score in the EVAR group (p < 0.001). A significant decrease in median length of stay at the intensive/intermediate care unit (5 vs. 2 days; p = 0.006) and length of in-hospital stay (20 vs. 12.5 days; p < 0.001) was observed during period 2. Overall perioperative mortality was reduced from 6.9% during the first period to 2.2% during the second period (p = 0.256). EVAR mortality was 0%, mortality after open repair was reduced from 8.5% to 3.7% (p = 0.414). In conclusion, by risk-adjusted selection of treatment and frequent application of EVAR, it is possible to improve perioperative outcome of elective AAA repair at a low-volume hospital. Mortality figures are similar to those of recent trials at high-volume centers, as reported in the literature.
多项研究发现,在手术量较低的中心,血管内动脉瘤修复术(EVAR)的死亡率较高,且应用率较低。本文介绍了血管内时代一家手术量较低的中心进行择期腹主动脉瘤(AAA)修复的结果,并研究在这种情况下,扩大EVAR的应用是否能改善术后死亡率。这是一项为期11.6年的回顾性队列研究,研究对象为1997年至2008年7月期间在一家三级医疗学术医院接受择期手术或血管内AAA修复的132例患者,即每年的手术量中位数为12例。根据EVAR各自的适应证和禁忌证,该研究分为两个时间段,2005年这些适应证和禁忌证发生了重大变化。在第1阶段,仅对瘤颈长度≥20 mm且不累及髂动脉的动脉瘤进行腔内治疗。从2005年开始,EVAR的适应证扩大到最小瘤颈长度为15 mm的主髂动脉瘤。术前风险通过SVS/AAVS合并症评分进行评估。在第1阶段(1997 - 2004年),所有患者中有18.4%(16/87)接受了EVAR。通过在2005年扩大EVAR的解剖范围和适应证,在第2阶段(2005年 - 2008年7月),EVAR的应用率提高到了40.0%(18/45);p = 0.007。在两个观察期内,术前风险因素的患病率没有变化。与第1阶段不同,在第2阶段,高危患者优先接受腔内治疗,导致EVAR组的SVS/AAVS评分中位数显著更高(p < 0.001)。在第2阶段,重症/中级护理病房的住院时间中位数显著缩短(5天对2天;p = 0.006),住院总时间也显著缩短(20天对12.5天;p < 0.001)。围手术期总体死亡率从第1阶段的6.9%降至第2阶段的2.2%(p = 0.256)。EVAR死亡率为0%,开放修复后的死亡率从8.5%降至3.7%(p = 0.414)。总之,通过风险调整后的治疗选择和频繁应用EVAR,有可能改善手术量较低医院择期AAA修复的围手术期结局。死亡率数据与文献中报道的近期高手术量中心试验的死亡率数据相似。